Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson's disease: a patent review of the literature to date.

Margaux MorezAntonio Jesús Lara OrdóñezPatricia MelnykMaxime LiberelleNicolas LebègueJean-Marc Taymans

Published in: Expert opinion on therapeutic patents (2024)

It can be expected that LRRK2 targeting strategies may proceed to phase III clinical testing for PD in the next five years, allowing the field to discover the real clinical value of LRRK2 targeting strategies.

Keyphrases

phase iii
clinical trial
cancer therapy
open label
double blind
randomized controlled trial
tyrosine kinase
phase ii
drug delivery
protein kinase